Legal & General Group PLC Viking Therapeutics, Inc. Transaction History

Legal & General Group PLC

$440 Billion
Q2 2024

A detailed history of Legal & General Group PLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 110,630 shares of VKTX stock, worth $7.29 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

110,630

Previous 96,287 14.9%

Holding current value

$7.29 Million

Previous $7.9 Million 25.73%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$47.39 - $80.2 $679,714 - $1.15 Million	14,343 Added 14.9%	110,630 $5.86 Million
Q1 2024 May 14, 2024	BUY	$17.4 - $94.5 $13,589 - $73,804	781 Added 0.82%	96,287 $7.9 Million
Q4 2023 Feb 15, 2024	BUY	$9.24 - $19.64 $8,371 - $17,793	906 Added 0.96%	95,506 $1.78 Million
Q3 2023 Nov 14, 2023	SELL	$10.92 - $16.0 $2,205 - $3,232	-202 Reduced 0.21%	94,600 $1.05 Million
Q2 2023 Aug 14, 2023	BUY	$14.84 - $24.79 $957,076 - $1.6 Million	64,493 Added 212.78%	94,802 $1.54 Million
Q1 2023 May 15, 2023	BUY	$8.08 - $17.33 $244,896 - $525,254	30,309 New	30,309 $504,000
Q2 2022 Aug 22, 2022	SELL	$2.11 - $3.15 $52,178 - $77,896	-24,729 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$5.58 - $7.04 $72,668 - $91,681	13,023 Added 111.25%	24,729 $156,000
Q2 2021 Aug 12, 2021	BUY	$5.19 - $6.73 $2,740 - $3,553	528 Added 4.72%	11,706 $70,000
Q1 2021 May 17, 2021	BUY	$5.74 - $9.67 $22,380 - $37,703	3,899 Added 53.57%	11,178 $70,000
Q3 2020 Nov 13, 2020	SELL	$5.73 - $8.11 $15,339 - $21,710	-2,677 Reduced 26.89%	7,279 $42,000
Q2 2020 Aug 14, 2020	BUY	$4.35 - $8.08 $2,583 - $4,799	594 Added 6.34%	9,956 $72,000
Q1 2020 May 14, 2020	SELL	$3.45 - $7.95 $11,474 - $26,441	-3,326 Reduced 26.21%	9,362 $44,000
Q4 2019 Feb 13, 2020	BUY	$6.38 - $8.73 $6,258 - $8,564	981 Added 8.38%	12,688 $102,000
Q1 2019 May 15, 2019	BUY	$7.58 - $9.94 $7,602 - $9,969	1,003 Added 9.37%	11,707 $116,000
Q4 2018 Feb 15, 2019	BUY	$7.16 - $16.21 $21,086 - $47,738	2,945 Added 37.96%	10,704 $82,000
Q3 2018 Nov 20, 2018	BUY	$9.7 - $19.65 $12,260 - $24,837	1,264 Added 19.46%	7,759 $135,000
Q2 2018 Aug 10, 2018	BUY	$3.88 - $12.74 $25,200 - $82,746	6,495 New	6,495 $62,000

Others Institutions Holding VKTX

# of Institutions

478

Shares Held

66.1M

Call Options Held

6.24M

Put Options Held

3.01M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $5.05B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Viking Therapeutics, Inc. Transaction History